# Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

> **NCT04723394** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 910 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** AZD7442
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04723394
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-28
- **Primary completion:** 2021-08-21
- **Final completion:** 2022-10-19
- **Target enrollment:** 910 (ACTUAL)
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04723394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04723394, "Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04723394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*